Merck’s Noxafil IV solution gains FDA priority review
This article was originally published in Scrip
Executive Summary
The US FDA granted a priority review to Merck's new drug application (NDA) for the firm's investigational intravenous (IV) solution formulation of its antifungal agent Noxafil (posaconazole).